We are live on ! Find out more
1.81 USD
+0.03
1.69%
At close Updated Jun 17, 12:42 PM EDT
1 day
1.69%
5 days
11.73%
1 month
33.09%
3 months
29.29%
6 months
24.83%
Year to date
36.09%
1 year
-82.43%
5 years
-99.9%
10 years
-99.82%
 

About: BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 13

0
Funds holding %
of 8,097 funds
0
Positive news %
of 8 articles
Price charts implemented using Lightweight Charts™